Literature DB >> 15533677

Determination of saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography and the analytical error function.

Verónica Albert1, Pilar Modamio, Cecilia F Lastra, Eduardo L Mariño.   

Abstract

Two simple and reproducible high-performance liquid chromatography methods with ultraviolet detection were developed and validated for the quantitation of two protease inhibitors, saquinavir and ritonavir, in human plasma. The same single liquid-liquid extraction procedure with ethyl acetate-hexane (50:50, v/v), reversed-phase column and mobile phase were used. The analyses were accomplished using a Luna C(18) column (150 mm x 4.6mm i.d.) with a C(18) guard column and, the mobile phase consisted of acetonitrile and 70 mM KH(2)PO(4) adjusted to pH 5 with 80 mM Na(2)HPO(4) (46:54, v/v). The wavelength was set at 240 nm for saquinavir and at 210 nm for ritonavir. The retention times were 6.4 min for saquinavir and 8.3 min for ritonavir. The methods were linear over the range of 100-2500 ng/ml for saquinavir and 200-2500 ng/ml for ritonavir. Intra and inter-day precision and accuracy were less than 10.2% for both drugs. Recovery were 90 and 87% for saquinavir and ritonavir, respectively. The drugs were stable at different relevant storage and working conditions. After the validation, their analytical error functions were established as standard deviation (S.D., ng/ml) = 4.84 + 7.14 x 10(-2)C (C is the theoretical concentration value) for saquinavir and S.D. (ng/ml) = 39.98 + 2.40 x 10(-5)C(2) for ritonavir.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15533677     DOI: 10.1016/j.jpba.2004.08.013

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

1.  Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort.

Authors:  Sarah M Robertson; Elizabeth Formentini; Raul M Alfaro; Ven Natarajan; Judith Falloon; Scott R Penzak
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

2.  Antiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064.

Authors:  Iris Chen; William Clarke; San-San Ou; Mark A Marzinke; Autumn Breaud; Lynda M Emel; Jing Wang; James P Hughes; Paul Richardson; Danielle F Haley; Jonathan Lucas; Anne Rompalo; Jessica E Justman; Sally L Hodder; Susan H Eshleman
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.